Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Metformin in ADPKD
NCT02903511Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Metformin with Placebo (2 arms). Primary endpoint: Safety and Tolerability of Metformin at 12 months. Started Nov 2016; status: completed.
02
Drugs
metformin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT02903511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903511.